CRISPR Therapeutics shares are trading lower after reports that Anthropic's Biolab has discovered a new enzyme system that resembles the Crispr gene editing tool.

Benzinga Newsdesk www.benzinga.com Negative 96.2%

Neg 96.2% Neu 0% Pos 0%

Comments

No comments yet. Be the first!